INSIGHTS ON CLINICAL TRIAL DESIGN

• High Density, Low Availability: Rethinking Ophthalmic Trial Readiness

  The adoption of mobile ophthalmic solutions and collaboration with specialized vendors is recommended to ensure trial consistency and reach underserved regions.

• Early Detection vs. Overdiagnosis: The ctDNA Screening Paradox

  Discover how ctDNA could transform early cancer detection and why the BRCA model offers important lessons for balancing innovation, risk, and meaningful patient outcomes.

• Five Preventable Clinical Design Pitfalls And How To Avoid Them

  While late-stage trial attrition is often attributed to inadequate safety or efficacy, the true failure may be insufficient upstream planning and/or misalignment between clinical and commercial goals.

• Rewriting The Code: Advances And Challenges In Pediatric Gene Therapy

  This presentation examines pediatric gene therapy and the three platforms now driving clinical progress: AAV vectors, lentiviral vectors, and CRISPR-based gene editing.

• Sustaining Participation In A 20-Year Alzheimer's Family Study

  8/14/2026

  Learn how home-based visits can reduce burden, improve retention, and support long-term follow-up in complex clinical studies requiring years of continuous participation.

• ASCO To EHA 2026: From Incremental Gains To Early Impact: What Biotechs Must Do Next

  9/28/2026

  Oncology is moving to earlier treatment. Learn how ASCO and EHA 2026 results can help you design faster, earlier-line trials that stay relevant as standards of care change and access gaps persist.

• Receptor Occupancy In The Era Of Multispecific Therapeutics

  8/21/2026

  Receptor occupancy studies face new challenges as multispecific therapeutics introduce complex target engagement, receptor trafficking, cellular interactions, and assay interpretation considerations.

• Collaborate To Improve The Patient Experience

  8/8/2026

  Fragmented trial operations trigger costly enrollment delays. Discover how operational alignment among sponsors, CROs, and site networks drives patient retention and study success.

• The Impact Of High Inflation And The Great Resignation On Clinical Site Budgeting

  10/30/2024

  The twin pressures of inflation and attrition prolong negotiations between sponsors and clinical sites, stalling drug development. Sponsors need up-to-date, reliable benchmark data to negotiate fair market value budgets.